Caruso Vincenzo, Bilkhu Rajdeep, Young Christopher, Roxburgh James, Bosco Paolo, Lucchese Gianluca
Cardiovascular Department, St. Thomas' Hospital, London SE1 7EH, UK.
J Clin Med. 2024 Jul 15;13(14):4126. doi: 10.3390/jcm13144126.
: In an era of growing evidence for transaortic valve implantation (TAVI), our research topic was the evaluation of how surgical aortic valve replacements (SAVRs) are performing in terms of short- and long-term outcomes in different risk categories. : This was a single centre, prospective, and observational cohort study of consecutive patients with aortic valve stenosis, undergoing isolated aortic valve replacement using a biological or mechanical prosthesis, Freestyle™ (Medtronic, Minneapolis, MN, USA) graft, homograft, or Ross procedure. The participant data were collected by review of an internal database. The primary endpoints were all-cause operative mortality (in hospital and at 30 days) and late mortality at the follow-up date. The secondary composite endpoint was the incidence of postoperative complications. : 1501 patients underwent SAVR; the mean age was 67 years (SD: 12.6). The in-hospital mortality was 1% ( = 16). At a median follow-up of 60 months, the survival rate was 98.7%. The main predictors for mortality were operative urgency and cardiogenic shock. The overall incidence of PPM was 2.3% ( = 34). Patients who underwent Ross procedure were younger (mean age: 20 years (SD: 1.7)), had a lower incidence of postoperative complications, and were all alive at follow-up. : SAVR shows an excellent survival rate and a low rate of postoperative complications despite an increasing surgical risk. Recent advancements in technology, like sutureless/rapid deployment prostheses and minimally invasive techniques, are shown to have favourable effects on outcomes.
在经导管主动脉瓣植入术(TAVI)证据日益增多的时代,我们的研究主题是评估外科主动脉瓣置换术(SAVR)在不同风险类别中的短期和长期结果表现。
这是一项单中心、前瞻性观察队列研究,研究对象为连续的主动脉瓣狭窄患者,他们接受了使用生物或机械假体、Freestyle™(美敦力公司,美国明尼阿波利斯,MN)移植物、同种异体移植物或罗斯手术的单纯主动脉瓣置换术。通过审查内部数据库收集参与者数据。主要终点是全因手术死亡率(住院期间和30天时)以及随访日期的晚期死亡率。次要复合终点是术后并发症的发生率。
1501例患者接受了SAVR;平均年龄为67岁(标准差:12.6)。住院死亡率为1%(n = 16)。在中位随访60个月时,生存率为98.7%。死亡率的主要预测因素是手术紧迫性和心源性休克。永久起搏器植入(PPM)的总体发生率为2.3%(n = 34)。接受罗斯手术的患者更年轻(平均年龄:20岁(标准差:1.7)),术后并发症发生率更低,且随访时全部存活。
尽管手术风险增加,但SAVR显示出优异的生存率和较低的术后并发症发生率。技术上的最新进展,如无缝合/快速部署假体和微创技术,已被证明对结果有有利影响。